Вторичная профилактика ишемической болезни сердца в клинической практике врача: выбор терапии
Аннотация
В обзоре изложены основные принципы вторичной профилактики ишемической болезни сердца. Обозначена важность применения для предупреждения сердечно-сосудистых осложнений как немедикаментозных воздействий – коррекция факторов риска, связанных с образом жизни, так и медикаментозных средств. Основу медикаментозной терапии составляют классы препаратов с доказанной профилактической эффективностью: статины и антиагреганты (обязательные компоненты), а также β-адреноблокаторы и ингибиторы ангиотензин-превращающего фермента (по показаниям).
Об авторе
М. Г. Бубнова
ФГУ Государственный научно-исследовательский центр профилактической медицины
Россия
Россия
Ведущий научный сотрудник лаборатории сочетанной патологии
Москва
Список литературы
1. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Eur. J. Cardiovasc Prevention and Rehabilitation 2007; 4 (Suppl.2).
2. 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients with Chronic Stable Angina. A Report of the ACC/AHA Task Force on Practice Guidelines Writing Group of Develop the Focused Update of the 2002 Guidelines for the Management of Patients with Chronic Stable Angina. Circulation 2007; 116: 2762-72.
3. Fox K, Garcia MAA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27:1341-81.
4. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trial for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-9.
5. Clinical Guidelines on the identification, evaluation and treatment of overweight and obesity in adults. The evidence report NIH Publication No 98-4083; 1998.
6. Alexander JK. Obesity and coronary heart disease. In: Alpert M.A., Alexander J.K. eds. The Heart and Lung in Obesity. Armonk, NY: Futura; 1998: 213-38.
7. Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA 1999; 282: 1530-8.
8. Аронов Д.М., Бубнова М.Г., Перова Н.В. и др. Физические нагрузки и атеросклероз: проатерогенное влияние статических нагрузок высокой и умеренной интенсивности на липидтранспортную систему крови. Кардиология 2003; 2: 35-9.
9. Бубнова М.Г., Аронов Д.М., Перова Н.В. и др. Физические нагрузки и атеросклероз: динамические физические нагрузки высокой интенсивности как фактор, индуцирующий экзогенную дислипидемию. Кардиология 2003; 3: 43-9.
10. Бубнова М.Г., Аронов Д.М., Перова Н.В., Зволинская Е.Ю. Физические нагрузки и атеросклероз: влияние динамических нагрузок разной интенсивности на показатели липидтранспортной системы и углеводного обмена у больных коронарной болезнью сердца и сахарным диабетом 2 типа. Кардиология 2005; 11: 33-40.
11. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC 2008; 51: 172-209.
12. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement. Results From rhe PREMIER Registry. Circulation 2006; 113: 2803-9.
13. Rosendoff C, Black HR, Cannon CP, et al. Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease. A Scientific Statement From the American Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115: 2761-88.
14. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1442-536.
15. Somes G, Pahor M, Shorr R, et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 1999; 159: 2004-9.
16. Boutitie F, Gueyffier A, Popock S, et al. for the INDANA Project Steering Committee. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from meta-analysis of individual-patient data. Ann Intern Med 2002; 136: 438-48.
17. Аронов Д.С., Соколова О.Ю, Гудковская Л.А. Воплощение идеи вторичной профилактики коронарной болезни сердца в реальной практике. Кардиоваск тер профил 2007; 6(1): 105-13.
18. Yusuf S, Sleight P, Pogue J, et al. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcome Prevention Evaluаtion (HOPE) Study Investigators. N Engl J Med 2000; 342: 145-53.
19. The EUROPA Investigator. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease; randomized, double-blind, placebo-controlled, milticentre trial (the EUROPA study). Lancet 2003; 358: 1033-41.
20. Бубнова М.Г., Перова Н.В., Аронов Д.М. и др. Синдром нарушенной толерантности к экзогенным (пищевым) жирам при коронарной болезни сердца. Кардиология 2003; 4: 36-42.
21. Karpe F, Steiner G, Uffelman K, et al. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994; 106: 83-97.
22. Бубнова М.Г., Аронов Д.М., Перова Н.В., Мазаев В.П. Связь уровня липемии после жировой нагрузки со степенью выраженности атеросклероза коронарных артерий. Тер архив 2004; 76(6): 62-7.
23. Smith DG, Leslie SJ, Szucs TD, et al. Cost of treating to a modified European Atherosclerosis Society LDL-C target. Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin. (Treat-to-Target Study). Clin Drug Invest 1999; 17: 185-93.
24. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al.. Efficacy and safety of a new HMG-CoA reductase inhibitor atorvastatin in patients with hypertriglyceridemia. JAMA 1996; 275: 128-33.
25. Naoumova R, Dunn S, Rallidis L, et al. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J Lipid Res 1997; 38: 1496-500.
26. Бубнова М.Г., Аронов Д.М., Перова Н.В. Липидкорригирующие эффекты низкой дозы аторвастатина у больных сахарным диабетом типа 2 и ожирением. Сахарный диабет 2003; 1: 30-4.
27. Метельская В.А. Особенности и механизмы действия аторвастатина: взгляд биолога (часть I). Атмосфера 2006; 3: 2-8.
28. Wissen S, Smide TJ, Groot E, et al. The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on atherosclerosis progression study. Eur J Cardiovasc Prevention Rehab 2003; 10: 451-5.
29. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA 2004; 291: 1071-80.
30. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxiamediated down-regulation of endothelial nitris oxide synthase. J Biol Chem 1997; 272: 31725-9.
31. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300-5.
32. Zhu Q, McMaster J, Mymin D, et al. Effects of atorvastatin treatment on the oxidatively modified low density lipoprotein in hyperlipidemic patients. Mol Cell Biochem 2000; 207: 9-17.
33. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effect of the 3hydroxy-3-methylglutaryl-Co A reductase inhibitors, atorvastatin and simvastatin in the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-9.
34. Riesen WF, Engler H, Risch M, et al. Short effect atorvastatin on C-reactive protein. Eur Heart J 2002; 23: 794-9.
35. Salbach P, Lang S, Küchler D, et al. Short term treatment with atorvastatin: decrease of inflammatory markers and binding activity of NF-kappaB in patient with hypercholesterolaemia (abstr.) Eur Heart J 2001; 22: 644.
36. Ortego M, Bustos C, Hernandez-Presa MA, et al. Atorvastatin reduces NF-kB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147: 253-61.
37. Laufs U, Gertz K, Huang P, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000; 31: 2442-9.
38. Tannous M, Cheung R, Vignini A, et al. Atorvastatin increase eNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost 1999; 82: 1390-4.
39. Alfon J, Palazon PC, Royo T, Badimon L. Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model. Thromb Haemost 1999; 81: 822-7.
40. Lopez S, Peiretti F, Bonardo B, et al. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-I in cultured human endothelial cells Atherosclerosis 2000; 152: 359-66.
41. Ne′gegre-Aminou P, van Vliet AK, van Erck M, et al. Inhibition of proliferation of human smooth muscle cells by various HMGCoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997; 1345: 259-68.
42. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103: 2885-90.
43. Satoh K, Ichihara K. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. J Cardiovasc Pharmacol 2000; 35: 256-62.
44. Pehlivanidis A, Athyros V, Demitriadis D, et al. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2001; 152: 463-9.
45. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-8.
46. Pitt B, Waters D, Brown WV, et al. for Atorvastatin versus Revascularization Treatment Investigators. Aggressive lipid-lowing therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70-6.
47. Boden WE, O`Rourke RA, Teo KK, et al. Design and rationale of the Clinical Outcome Utilizing Revisualization and Aggressive Drug Evaluation (COURAGE) trial. Am Heart J 2006; 151: 1173-9.
48. Boden WE, O`Rourke RA, Teo KK, et al. The Evolving Pattern of Symptomatic Coronary Artery Disease in the United States and Canada: Baseline Characteristics of the Clinical Outcome Utilizing Revisualization and Aggressive Drug Evaluation (COURAGE) Trial. Am J Cardiol 2007; 99: 208-12.
49. Boden WE, O`Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356(15): 1503-16.
Рецензия
Для цитирования:
Бубнова М.Г. Вторичная профилактика ишемической болезни сердца в клинической практике врача: выбор терапии. Кардиоваскулярная терапия и профилактика. 2009;8(8):97-107.
For citation:
Bubnova M.G. Secondary prevention of coronary heart disease in clinical practice: choosing the treatment. Cardiovascular Therapy and Prevention. 2009;8(8):97-107. (In Russ.)
Просмотров:
1468
Послать статью по эл. почте 
